Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 1/2020

EVALUATION OF MICONAZOLE NITRATE PERMEABILITY THROUGH BIOLOGICAL MEMBRANE FROM DERMAL SYSTEMS

MAGDALENA BÎRSAN 1,3, ANA CATERINA CRISTOFOR 2, PAULA ANTONOAEA 3, NICOLETA TODORAN 3*, NELA BIBIRE 4, ALINA DIANA PANAINTE 4, ROBERT ALEXANDRU VLAD 3, MIHAELA GRIGORE 5, ADRIANA CIURBA 3

1.“Grigore T. Popa” University of Medicine and Pharmacy of Iași, Departament of Pharmaceutical Sciences II, 16 Universității Street, Iași, Romania
2.“Grigore T. Popa” University of Medicine and Pharmacy of Iași, Medical Department III, 16 Universității Street, Iași, Romania
3.University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, Department of Pharmaceutical Technology and Cosmetology, 38 Gh. Marinescu Street, Târgu Mureș, Romania
4.“Grigore T. Popa” University of Medicine and Pharmacy of Iași, Departament of Pharmaceutical Sciences I, 16 Universității Street, Iași, Romania
5.“Grigore T. Popa” University of Medicine and Pharmacy of Iași, Department of Obstetrics and Gynaecology, 16 Universității Street, Iasi, Romania

Download Full Article PDF

The development of pharmaceutical products with miconazole nitrate (MN) can bring various benefits to patients of whom fungal infections are resistant to classic antifungal formulas. In medical practice, dermal systems, in the form of polymeric films, represent an alternative to other medical products. The proposed dermal films contain hydroxyethyl cellulose (HEC) as a hydrophilic and bioadhesive matrix polymer, with the addition of polyethylene glycol (PEG) as a low-absorption promoter, so that the antifungal have a slow penetration towards the dermis. This study aims to evaluate the in vitro permeability of MN through biological membrane (pig ear skin) at pH 7.4, during its release from two polymeric films. In vitro pig ear skin permeation studies indicated that the amount of the drug released after 24 h was 40% in the case of formulation FI and 32% in the case of formulation FII from the initial dose (40 mg). The concentration of 40% MN released can be considered an appropriate antifungal dose, with the benefit of being accumulated in the stratum corneum where it is maintained for up to 4 days.